Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
about
New therapies for treating Down syndrome require quality of life measurementSynthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporterSynthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporterCognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome.Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up.Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date.Challenges in measuring the effects of pharmacological interventions on cognitive and adaptive functioning in individuals with Down syndrome: A systematic review.
P2860
Q22252951-1C4998DD-BB65-4C6F-9BF5-87883BCC9CAFQ24650088-D2E22BE9-AFEC-4897-B429-C48843914D17Q33786537-568442C1-8AAF-48C7-8534-179E40900BD4Q34305075-A7599E30-1F04-4458-88B0-7542323855B1Q34511717-EFB2FFDE-0623-4C92-8E83-54A644743E04Q38675507-A322CAFA-8287-4817-BB25-C993B3AFD4EAQ51930325-F9897244-F33B-4BC9-A462-6E8630F831AAQ53081143-F40F42BD-DAB0-495D-B208-3A64BAE97393Q53089871-9548345D-D30C-4EFD-8031-680E324A1972
P2860
Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Safety and efficacy of rivasti ...... ary 20-week, open-label study.
@ast
Safety and efficacy of rivasti ...... ary 20-week, open-label study.
@en
type
label
Safety and efficacy of rivasti ...... ary 20-week, open-label study.
@ast
Safety and efficacy of rivasti ...... ary 20-week, open-label study.
@en
prefLabel
Safety and efficacy of rivasti ...... ary 20-week, open-label study.
@ast
Safety and efficacy of rivasti ...... ary 20-week, open-label study.
@en
P2093
P2860
P356
P1476
Safety and efficacy of rivasti ...... ary 20-week, open-label study.
@en
P2093
Blythe G Crissman
Gail A Spiridigliozzi
James H Heller
Jennifer A Sullivan
Jennifer S Li
K Ranga Krishnan
P Murali Doraiswamy
Priya S Kishnani
Rebecca L Eells
P2860
P304
P356
10.1089/CAP.2006.16.755
P577
2006-12-01T00:00:00Z